Oncology

FDA approves the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR TKIs in the treatment of EGFR-mutated non–small cell lung cancer.

The FDA granted priority review to a supplemental biologics license application for cemiplimab-rwlc for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer.

Approximately 30% of women gain weight following chemotherapy for breast cancer, gut bacteria may be why.

The FDA granted priority review to a supplemental biologics license application for trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma.

FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.

Lipid-lowering medication may be an effective adjuvant cancer therapy.

The FDA has approved the FoundationOne CDx (F1CDx) comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.

Cholesterol-lowering statins have been found to potentially reduce the risk of cancer via a pathway that is unrelated to its impact on cholesterol, according to a recent study.

Patients with current or former smoking status may be at an increased risk of severe illness due to COVID-19.

The FDA granted osimertinib (Tagrisso) priority review designation for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

oNKord is a natural killer cellular immunotherapy product, meaning it can play an important role in controlling and curing both solid and hematological malignancies.

Pembrolizumab (Keytruda) has demonstrated promising activity when used in combination with chemotherapy or quavonlimab in select patients with nonsquamous non–small cell lung cancer.

The Mary Pazdur Award was presented during the JADPRO Live Virtual conference.

Pharmacy Times® interviewed Petros Grivas, associate professor at the University of Washington and Fred Hutchinson Cancer Research Center and a medical oncologist at Seattle Cancer Care Alliance, on the value of the pharmacist in the treatment of patients with cancer during COVID-19.

Top news of the week from Pharmacy Times.

Women diagnosed with cancer as adolescents or young adults can be especially vulnerable to the impact of the disease and its treatment on their ability to work.

Despite it being fall, sun safety is important all year and even needs to be considered for winter sport activities, such as snowboarding and skiing.

Evidence-based cancer regimens have been shown to result in better outcomes, including longer survival and less toxicity.

The COVID-19 pandemic has caused many routine colorectal cancer screenings to be delayed.

The research found that obese patients with diabetes were significantly less likely to develop pancreatic cancer if they had undergone bariatric surgery, with the majority of the patients in the study being female.

Enfortumab vedotin-ejfv (Padcev) elicited durable responses in patients with locally advanced or metastatic urothelial cancer who received previous treatment with a PD-1/PD-L1 inhibitor.

The authors concluded that a single dose of targeted intraoperative radiotherapy should be an option accessible to health care providers and discussed with patients.

Bacteria in the gut may play a role in the treatment outcomes of patients with prostate cancer taking oral medications, according to a recent study.

Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.

IMGN632 granted breakthrough designation for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

Patients should talk to their health care team about when to reschedule a postponed or cancelled screening appointment.

Nivolumab plus ipilimumab is the first immunotherapy approved for previously untreated unresectable malignant pleural mesothelioma.